36E79720R0068_1.docx
DOCX document 16 KB Posted
- Solicitation number
- 36E79720R0068
About this file
This document is a pre-solicitation notice for Request for Proposal 36E79720R0068 to provide subcutaneous anti-interleukin monoclonal antibodies for asthma to the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, and Indian Health Service. The VA intends to award a one-year contract with four one-year option periods to supply mepolizumab, dupilumab, and benralizumab in various dosages and package configurations. Interested offerors should continuously monitor the FedBizOpps website for solicitation documents to be issued on September 16, 2020, with responses due by September 30, 2020. The estimated annual patient populations are 3,880 for VA, 552 for DoD, 18 for BOP, and 200 for IHS, totaling approximately 4,650 patients. Offerors must specify the exact product name and National Drug Code number for the antibodies to be provided. The point of contact is Chris Carthron and any questions should be directed to Christopher.Carthron@va.gov.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Contract Opportunity Presolicitation Notice
PRODUCT SERVICE CODE
SUBJECT
CONTRACTING OFFICE'S
ZIP-CODE
SOLICITATION NUMBER
RESPONSE DATE/TIME/ZONE
ARCHIVE
DAYS AFTER THE RESPONSE DATE
RECOVERY ACT FUNDS
SET-ASIDE
NAICS CODE
CONTRACTING OFFICE
ADDRESS
POINT OF CONTACT
(POC Information Automatically Filled from User Profile Unless Entered)
DESCRIPTION
See Attachment
AGENCY'S URL
URL DESCRIPTION
AGENCY CONTACT'S EMAIL
ADDRESS
EMAIL DESCRIPTION
ADDRESS
POSTAL CODE
COUNTRY
ADDITIONAL INFORMATION
GENERAL INFORMATION
PLACE OF PERFORMANCE
* = Required Field Contract Opportunity Presolicitation Notice Subcutaneous Anti-Interleukin Monoclonal Antibodies for Asthma (VA-21-00000590) 60141 36E79720R0068 N 325412 Department of Veteran's Affairs OPAL / National Acquisition Center Building 37, NCS (003B6C3) 1st Avenue, One Block North of Cermak Hines, IL 60141 Chris Carthron
Christopher.Carthron@va.gov Christopher.Carthron@va.gov PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79720R0068 for an unrestrictive procurement for Anti-Interleukin Monoclonal Antibodies for Asthma, for the Department of Veterans Affairs (VA), Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA’s and DOD’s respective Pharmaceutical Prime Vendor Programs. Offerors must state the exact name (name that appears on label) by which the antibodies will be supplied and have a unique NDC number. Solicitation #36E79720R0068 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about September 16, 2020, with a tentative closing date of September 30, 2020. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at the following URL: http://www.fedbizopps.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check this URL for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Chris Carthron. Questions can be e-mailed to: Christopher.Carthron@va.gov.
The estimated annual requirements are as follows:
| ITEM |
| Packages |
| DESCRIPTION |
| Dosing |
| Doses/Year |
| 1a |
| 1 |
| MEPOLIZUMAB 100MG/VIL INJ |
| 100mg Q 4 weeks |
| 13 |
| 1b |
| 1 |
| MEPOLIZUMAB 100MG/ML,AUTO INJCT |
| 100mg Q 4 weeks |
| 13 |
| 1c |
| 1 |
| MEPOLIZUMAB 100MG/ML,SYRINGE |
| 100mg Q 4 weeks |
| 13 |
| OR |
| OR |
| OR |
| OR |
| OR |
| 2a |
| 1 |
| DUPILUMAB 150MG/ML INJ,SYR,2ML 2 SYRINGES PER PACK |
| 400-600mg loading dose then 200mg or 300mg every other week |
| 13 packs of 2, or 26 syringes |
| 2b |
| 1 |
| DUPILUMAB 200MG/1.14ML INJ,SYR 2 SYRINGE PER PCK |
| 400-600mg loading dose then 200mg or 300mg every other week |
| 26 |
| OR |
| OR |
| OR |
| OR |
| OR |
| 3a |
| 1 |
| BENRALIZUMAB 30MG/ML INJ,SYR,1ML |
| 30mg Q 4 weeks x 3 doses then Q 8 weeks |
| 6.5 |
| 3b |
| 1 |
| BENRALIZUMAB 30MG/ML INJ,PEN,1ML |
| 30mg Q 4 weeks x 3 doses then Q 8 weeks |
| 6.5 |
| Agency |
| Number of Patients For Respiratory Use Only |
| VA |
| 3,880 |
| DoD |
| 552 |
| BOP |
| 18 |
| IHS |
| 200 |
Total Estimated Patients Annually 4,650
File details come from the government source that posted it. Updated .